WO2004024129A1 - Therapie induisant une remission - Google Patents

Therapie induisant une remission Download PDF

Info

Publication number
WO2004024129A1
WO2004024129A1 PCT/IB2002/005427 IB0205427W WO2004024129A1 WO 2004024129 A1 WO2004024129 A1 WO 2004024129A1 IB 0205427 W IB0205427 W IB 0205427W WO 2004024129 A1 WO2004024129 A1 WO 2004024129A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
immune
cells
disease
cell
Prior art date
Application number
PCT/IB2002/005427
Other languages
English (en)
Inventor
Samir Chachoua
Original Assignee
Samir Chachoua
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samir Chachoua filed Critical Samir Chachoua
Priority to PCT/IB2002/005427 priority Critical patent/WO2004024129A1/fr
Priority to AU2002353346A priority patent/AU2002353346A1/en
Publication of WO2004024129A1 publication Critical patent/WO2004024129A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Definitions

  • IRC metabolic immunity refers to the capacity for rapidly dividing tissue to limit and or consume a foreign invader. Metabolic immunity is activated strongly under three main parameters:
  • a cancel ⁇ ell has often been thought to be the result of a .andom mutation. 1 his explanation fails for many reasons, most obviously random mutations should behave In a random way , However, a cancer of a particular type in thousands of people of different races, geographic locations and environmental factions will almost always behave in exactly the same way. For example, bowel cancer of a certain kind will exhibit similar growth patterns and virtually identical areas m times of spread, regardless of particulars of the host carrying if, Cance l s also tend to occur in clusters of age groups, again making the idea thai they are random mutations scientifically silly.
  • Cancer cells can spread through (he blood-brain barrier, in chai ⁇ cteristic only shared by white blood immune cells, Cancer cells were found to be powerful immune stimulants by Simon Roosenfelt at NCi. Cancer cells produce powerful "anticancer compounds''' such as intraserurn. Lancer cells carry specific information lor melastases and for drug resistance. When a cancer is eliminated, anothei kind will often arise in its place. Cancer can be caused by so many different agents that it is again, scientifically harmless lo believe that smoking, radiation, and viruses can all cause identical genetic random mutations. Cancer is not a disease, it is a preprogrammed cellular response to disease. Every cell contains this programming and it does not take advantage of a weakened immune response but rather uses its capacity f ⁇ i encapsulation, metabolic elimination, and disease attenuation to supplement a weaker red immune response.
  • Cancer cell genelics are fluids and capable of surviving in chaos. This means that they can house several infections and toxic agents and remain alive, Under ideal circumstances, cancer cells probably only arise for a short time to hold and restrain an invader until the, appropriate immune response can be generated for its elimination. In a classic experiment done by Dr Chachoua, telanus, injected into rats would not kill them if cancer cells were injected along side- Actually if ihe infection followed the cancer rnoculaiion by up to two or throe weeks, neither the cancer nor the infection resulted.
  • cancer cells will often revert back to their normal coll or stem cell origins. If an acute infection stimulates rapid white cell growth or an immune response against the cancer cause, cancer often will resuil , Similarly if cancer is implanted next to rapidly gtowing tissue like the regenerating stump of a salamander's arm, or the notocords of the developing embryo, rancor will change back info normal cellular structures.
  • Chachoua's view correcting the cell's inability to directly deal with intracellular pathology, Mechanisms that every healthy coll has to destroy foreign invaders seem to be lacking in autoimmune disease, and the body appears to be responding to an agent such as a retro virus, as in Ihe case of CALV tti goals, by generating an antiserum to deal with the foreign pathogen. As in ihe case of malaria and thalassanamia, disease appears to confer an evolutionary advantage.
  • the animal model is particularly spectacular when one considers that Crown Gall transformation occurs after the bacterium donaios its phage to the surrounding plant calls, and Ihe same tan be found lo happen in cancei cells which contain phages of both bacteiia * m ⁇ microbe bacterial
  • a class of viruses similar to M-P and retro viruses can all interfere with HIV replication, T his could be by the phenomena of viral interference or by direct competition for HIV assembly and metabolic pathways.
  • HIV infected cells overwhelm the intiacellular immune mechanisms of destruction at least tit part by inserting info the DNA matrix and appearing to be part of fhe cell, The suppression of ihe mlracellul i lesponses against palhogens, while similar in effect lo what occurs in cancer cells, tenders HIV Infected cells even more susceptible to I Dr. Chachoua's tagging mechanisms,
  • a cancer cell cannot be outwardly recognized by the Immune response as pathologic. All of ⁇ 1s sinister actions and mechanisms are hidden within it; however, a cancer cell that is Infected with a readily recognisabl agent such as measles or mumps, will express these antigens on the cell surface for a shot! time period, usually two to thiee weeks. These agents then become entrapped and enclosed within the next generation of cancer cells, and although present within the cancer cell, no longer multiply and express their antigens on the cancel cell surface, This theiefoie gives a limited time window for the immune response lo rush in and attack the tagged cancer cell, while the invaders' antigen shine like beacons on its surface. I lowever, once Ihe invader is subjugated by the cancer and antigens ceased expressing on the cancer suiface, the immune system again becomes blind.
  • a readily recognisabl agent such as measles or mumps
  • Dr. Chachoua can optimize and plan for optimum immune cell and antiserum levels at the time when cancer expresses the agent's antigens. If optimum immune response occurs within three or four weeks, for example, Dr. Chachoua may prime the immune system two weeks prior to insertion of the tagging agent. This would allow for optimum expression and optimum immune response to occur simultaneously leading to a large cancer cell kill.
  • Tagging agents where their single DNA are in A strands or more complex fragments, or even whole viral or other microbial entities, will express with a gradience hundreds of times greater in cancer cells because of the lack of the cancer's ability to activate the standard intracellular immune responses.
  • This method of delaying maximum viral expression and maximum immune response largely relies on cortisone administration and- is designed to allow large levels of viral expression to occur, but has never shown therapeutic potential in the past, and can easily overwhelm a patient and further immune suppress them.
  • the tagging agents may be reactivated.
  • viruses which may not even be related can trigger their reappearance as can other infections.
  • Dcspile a cancer cell's genetic fluidify certain agents can bind in line genetic matrix and minimize a, ancer cell's ability lo deal with olher insults, such as other modalities of therapy.
  • a very applicable example is In D ⁇ . Chachoua's pafenl application where prior phagc infection o ⁇ a baclerium can not only lead to direct bacterial destruction but upon possible synergy between phage and bacteria, the synergistic phage or that lysogensed prevents infection by another phage which may cany genetics needed for antibiotic resistance for example.
  • the not-quile dormant initial tagging agent can be used to rebuild fragments from a secondary lagging agent.
  • Secondary tagging is even more specific than primai y lagging, as only Ihe cancer cells which carry the first agent will bo able to receive and lebuild Ihe secondary tagging agent.
  • These consecutive generations of tagging bolh allow for increases in the windows of opportunity as well as repetition for windows of opportunity, as oven Ihe primaiy tagging agent may be reassembled once the cell is carrying the other viruses or microbes that can reassemble ii. Very precise lagging can occur particularly whore more than one agent is needed to reassemble the new vaccine.
  • HIV infection With HIV infection, the cell lacks intracellular mechanisms of pathogen destruction, and hi essence has already le elved Its primary tagging agent Unfortunately," the immune responses elicited by this virus are either ineffective or deficient.
  • an aiuX HIV antiserum may actually piomote viral infection.
  • viral mutation or dormant existence of virus can easily bypass both immune and pharmaeologie mechanisms of ireatmeni. of th ⁇ above scenarios, viral reactivation offers the best and most focused therapeutic option,
  • the ptesenee of HIV allows fragments from a wide range of lelro viruses to be reassembled by HIV machinery.
  • Fragments of FPLV can be reassembled and yield powerful antigens foi immune destiuction of HIV Infected cells which attract an immune l esponsc both resistant to HIV and which can also act oveiwhelmingly in a rejection reaction againsl CAT -related antigens.
  • An anfiserum fio people exposed to this virus ot this vaccine can be useVi to optimive the window of opportunity as refc ted to above,
  • CAEN is a virus that has shown rlself 10 be innocuous in humans, as many fatrnei aie exposed to it.
  • the seia are IGG fragments close to Rh factor band
  • CAEV CAEV
  • Crude antibiotic culture preparations are capable of both tagging viral disease as well as providing strong antiviral activity, Although Induced Remission Therapy includes multiple agents isolated from tumor cells and fluid, such agents are likely to require further definition and would be much more difficult to readily incorporate in human testing, Crude antibiotics preparation; however, can be provided with supplements as many are so ⁇ rced from food type origins. .Supplementation of the crude cultural extract one leaspoon three times a day have led to nearly ⁇ ndet ⁇ clable viral levels after a six week treatment course, Precise preparation and formulations can be manufactured under GMT conditions and formulations can be provided upon signing of confidentiality agreement,.
  • Cystoamine was first proposed by Dr. Chachoua in the treatment- of AIDS because of animal trials that showed reversal of T4/T8 imbalance in animal lupus models as far back as '(982, Cysteanilne can both interfere with viral replication as well as act as an immune stimulant Cystean ⁇ sne may also Increase permeability and facilitate entry of antisera, In order to further inhibit: additional infections which may aggravate the progress of AIDS, Chachoua recommen s the addition of BHT mutilated hydroxy toluene in as high a conc mtration as 1 % pi>r volume of dietary intake or at least ⁇ nlo 500 milligrams TDS.
  • Intracellular antis ⁇ ra mono or polyclinal represents a new generation In immunolherapy and can be used either as sole agent or bound with che otherapeutic or radioactive agents for direct: delivery in the heart of the- cells being targeted.
  • a range of antibiotic agents as referred to above and immune sera as referred to above can also be designed to precipitate under certain conditions and crystallize on contact with their target antigen or organism or metabolic condition such as fluid Fh, within the target cell. This leads to a structural disruption and breakup of the disease cell.
  • This crystallization and subsequent, shredding of the pathological agent represents a combination of biochemical an physical pathways being incorporated into the one therapeutic arid provides double mechanisms against which mi.Uav.iona! resistance is unlikely lo develop,
  • BCG is a powerful immune stimulant, preventive against tuberculosis, anti-cancer agent? ; In common use against bladder cancer, As tuberculosis often occurs in AIDS patients, BCG vaccination would make a logical pr ⁇ ventat ⁇ v ⁇ easure.
  • the above concepts and agents > ⁇ combination with this ptcventative measure could yield an effective therapeutic method.
  • Immune stimulation by weekly punctures or other agents in the absence of active viral replication enables a uninfcclcd supply of T-cells to be generated.
  • Alternatives such as cross -matched T ceils transfusions protected by tagging agents or anlisera can also bo used but a unlikely to be as successful ' as fho patient's own.
  • Application of broad spectra antis ⁇ ra with intracellular components will protect the newly formed cells from infection as would many of the afoionientioned tagging agents.
  • BCG Iysates can be introduced into (he body. Ibeso will be reactivated a ' nd their antigens expressed only within HIV infected cull (as would other bacterial Iysates), This would yi ⁇ ld a strong immune result targeted at HIV infected cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des méthodes de traitement d'un patient atteint d'une maladie de type: (i) cancer; (ii) syndrome de déficience auto-immune; ou (iii) affection cardiaque. Ledit traitement consiste à provoquer une rémission par un des mécanismes suivants: encapsulation d'une substance biologique étrangère, (ii) déclenchement d'une immunité métabolique ou élimination, (iii) marquage d'une cellule ou autre substance biologique indésirable au moyen d'un antigène différent de celui de la cellule ou de la substance biologique indésirables, (iv) déclenchement d'une mutation de la cellule ou de la substance biologique indésirables, (v) administration d'un vaccin intracellulaire, (vi) administration de cystéamine, ou (vii) administration du BCG.
PCT/IB2002/005427 2002-09-10 2002-09-10 Therapie induisant une remission WO2004024129A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/IB2002/005427 WO2004024129A1 (fr) 2002-09-10 2002-09-10 Therapie induisant une remission
AU2002353346A AU2002353346A1 (en) 2002-09-10 2002-09-10 Induced remission therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005427 WO2004024129A1 (fr) 2002-09-10 2002-09-10 Therapie induisant une remission

Publications (1)

Publication Number Publication Date
WO2004024129A1 true WO2004024129A1 (fr) 2004-03-25

Family

ID=31985964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/005427 WO2004024129A1 (fr) 2002-09-10 2002-09-10 Therapie induisant une remission

Country Status (2)

Country Link
AU (1) AU2002353346A1 (fr)
WO (1) WO2004024129A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120086A1 (fr) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition du système de clivage de la glycine pour le traitement du cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006832A1 (fr) * 1991-09-30 1993-04-15 Thoene Jess G Procede de traitement d'infections a vih
WO1997011667A2 (fr) * 1995-09-25 1997-04-03 Samir Chachoua Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
AU6941196A (en) * 1995-09-15 1997-04-17 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
WO1997033615A2 (fr) * 1996-03-15 1997-09-18 University Of Southern California Virus de l'arthrite/encephalite caprine assurant une immunoprotection contre l'infection due au vih-1
US5756666A (en) * 1993-10-19 1998-05-26 Ajinomoto Co., Inc. Peptides capable of inducing immune response to HIV

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006832A1 (fr) * 1991-09-30 1993-04-15 Thoene Jess G Procede de traitement d'infections a vih
US5756666A (en) * 1993-10-19 1998-05-26 Ajinomoto Co., Inc. Peptides capable of inducing immune response to HIV
AU6941196A (en) * 1995-09-15 1997-04-17 Samir Chachoua Method for the identification and therapeutic use of disease-associated organisms, elements and forces
WO1997011667A2 (fr) * 1995-09-25 1997-04-03 Samir Chachoua Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
WO1997011666A2 (fr) * 1995-09-25 1997-04-03 Samir Chachoua Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies
WO1997033615A2 (fr) * 1996-03-15 1997-09-18 University Of Southern California Virus de l'arthrite/encephalite caprine assurant une immunoprotection contre l'infection due au vih-1

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HIROI T. ET AL.: "HIV mucosal vaccine: nasal immunization with rBCG-V3J1 induces a long term V3J1 peptide-specific neutralizing immunity in Th1- and Th2-deficient conditions", THE JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 5862 - 5867 *
LETVIN N.L. ET AL.: "Prospects for vaccines to protect against AIDS, tuberculosis and malaria", JOURNAL OF AMERICAN MEDICAL ASSOCIATION, vol. 285, no. 5, February 2001 (2001-02-01), pages 606 - 611 *
LEUNG N.J. ET AL.: "The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gg, Pol, Env and Nef proteins", VIROLOGY, vol. 268, 2000, pages 94 - 103 *
MCSHANE H.: "Prime-boost immunization strategies for infectious diseases", CURRENT OPINION IN MOLECULAR THERAPEUTICS, vol. 4, no. 1, February 2002 (2002-02-01), pages 23 - 27 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013120086A1 (fr) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition du système de clivage de la glycine pour le traitement du cancer
US9493775B2 (en) 2012-02-10 2016-11-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer

Also Published As

Publication number Publication date
AU2002353346A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
Kobayashi et al. Treatment of 37 patients with anaplastic carcinoma of the thyroid
CA2233015A1 (fr) Utilisation therapeutique de serums d'animaux, en particulier du cheval, pour le traitement du sida, du cancer et d'autres maladies virales et bacteriennes
Mohapatra et al. Dietary multispecies probiotic supplementation enhances the immunohematological responses and reduces mortality by Aeromonas hydrophila in Labeo rohita fingerlings
WO2004024129A1 (fr) Therapie induisant une remission
Hussain et al. Anticoccidial potential of Ageratum conyzoides and its effect on Blood parameters of experimentally infected Broiler Chickens
Tripathi et al. Efficacy of W ithania somnifera chemotypes NMITLI–101R, 118R and Withaferin A against experimental visceral leishmaniasis
WO2007100628A9 (fr) Destruction de spores au moyen d'une phagocytose renforcée par un glycoconjugué
Blessing et al. Antimalarial activity of crude extract and fractions of Phyllanthus amarus in plasmodium berghei-infected mice
Burger Evidence of the Existence of a Large Amount of Cationic Antimicrobial Peptides in Propolis, with a Strong Physical/Electrostatic Mechanism of Action (Detergent-like), and their Possible Promising Effects in the Treatment of COVID-19 by means of Propolis Extract Inhalation
Perera et al. Biotoxins: Invisible threat to mankind
Polglase Immunization against Ehrlich's ascites carcinoma with Streptomycin complexes from tumour cells
Kaihena et al. The Effect of the Petroleum Ether Extracts from Mangosteen Pericarp (Garcinia mangostana L.) on Interferon-gammaand, Interleukin-12 Activities in AlbinoWistar Rats (Rattus norvegicus) Infected with Mycobacterium tuberculosis
Loos Bacteria and complement
HUSSAIN Copyright© 2021 K HUSSAIN, RZ ABBAS, A ABBAS, K SAMIULLAH, T AHMED, F SIDDIQUE, M MOHSIN, A REHMAN, A. UL RAHMAN, MU WAQAS
Ikechi et al. COVID-19 Vaccines and Vaccination Report: The Nigeria Perspective
Van der Waaij The last epidemic: Selective decontamination in the control of mortality among radiation victims.
CA2232086A1 (fr) Procede d'identification et d'utilisation therapeutique d'organismes, d'elements et de forces associes a une maladie
Shaheen et al. Effect of methanolic extract of Citrus limetta peel on cellular and humoral immune response in mice.
AU7250300A (en) Therapeutic applications of animal sera including horse serum in the treatment of aids, cancer, and other viral and bacterial diseases
Ghoneum One sizeable step for immunology, one giant leap for cancer patients
Erciyas Murrembeena (AU)
EP4164684A2 (fr) Inactivation du génome enveloppé dans des particules ou des enveloppes sphériques ou pléomorphes de coronavirus pour former un vaccin
Oladosu Comments on Antituberculosis Activity of Bioactive Compounds from Acacia Nilotica
Gray et al. The effects of varying dosages of irradiation on benign and malignant pelvic lymph nodes.
CA2622997C (fr) Composition liposomique causant une lyse de cellules et de pathogenes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase